Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | AHCY | P23526 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285483 | 1.00 | MEN1 (0.40) | MEN1KMT2APRMT5NR1D1KDM4E | |
| SCHEMBL28491911 | 0.90 | HRH3 (0.38) | HRH3 | |
| SCHEMBL18285579 | 0.88 | PRMT5 (0.41) | MEN1KMT2APRMT5KDM4ENPC1 | |
| SCHEMBL18285582 | 0.88 | PRMT5 (0.41) | MEN1KMT2APRMT5KDM4ENPC1 | |
| SCHEMBL23450710 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2ANR1D1SLC2A1 | |
| SCHEMBL30111806 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2ANR1D1SLC2A1 | |
| SCHEMBL18290014 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2ANR1D1SLC2A1 | |
| SCHEMBL15710384 | 0.82 | PRMT5 (0.44) | MEN1KMT2APRMT5L3MBTL1GPR119 | |
| SCHEMBL15710382 | 0.82 | PRMT5 (0.44) | MEN1KMT2APRMT5L3MBTL1GPR119 | |
| SCHEMBL18285457 | 0.81 | OPRD1 (0.42) | MEN1KMT2APRMT5KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3303334-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | MEN1 2187/4885KMT2A 1622/4885PRMT5 1192/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | MEN1 2187/4885KMT2A 1622/4885PRMT5 1192/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | MEN1 2187/4885KMT2A 1622/4885PRMT5 1192/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | MEN1 2187/4885KMT2A 1622/4885PRMT5 1192/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | MEN1 2187/4885KMT2A 1622/4885PRMT5 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.